In spite of the challenging climate to raise capital, a North Carolina biotech company raised $42.5 million for its kidney-focused cancer drug.
Related Posts
-
“TVC National Summit” set for next month in Chattanooga
May 05 2014
-
Survey of JA Gen Zers confirms strong desire to be an entrepreneur
May 24 2021
-
Mayo Clinic, Boston Scientific team-up to launch new med-tech accelerator
Aug 05 2019
-
MIT.nano announces new pilot program to learn how best to help nanotech start-ups
Jun 03 2021
-
Value proposition is an important goal
Oct 31 2013
-
Frank Hutchison provides update on SH Data Technologies progress
Sep 12 2018
Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to tballard@pyapc.com. Include the name and contact information (phone and email) for follow-up.